Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, GlucoNorm in Canada, Surepost in Japan, Repaglinide in Egypt by EIPICO, and NovoNorm elsewhere. In Japan it is produced by Dainippon Sumitomo Pharma. Medical uses
Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus. Contraindications
Repaglinide is contraindicated in people with:

Diabetic ketoacidosis, with or without coma
Type 1 diabetes
Co-administration with gemfibrozil
Known hypersensitivity to drug or inactive ingredients

Adverse events
Common adverse events include:Metabolic 

Hypoglycemia (31%)Respiratory

Upper respiratory infection (16%)
Sinusitis (6%)
Rhinitis (3%)Gastrointestinal

Nausea (5%)
Diarrhea (5%)
Constipation (3%)
Vomiting (3%)Musculoskeletal

Arthralgia (6%)
Back Pain (5%)Other

Headache (11%)
Paresthesia (3%)Serious adverse events include:
Cardiac ischemia (2%)
Angina (1.8%)
Deaths due to cardiovascular events (0.5%)

Special populations
Pregnancy category C: safety in pregnant women has not been established. Data is limited, and there is only one case report that notes no complications with the use of repaglinide during pregnancy.Caution should be taken in people with liver disease and decreased kidney function when using this medication. Drug interactions
Repaglinide is a major substrate of CYP3A4 and should not be administered concomitantly with gemfibrozil, clarithromycin or azole antifungals such as itraconazole or ketoconazole.
At approximately the end of the 7th and the beginning of the 8th week of gestation, the Sertoli cells secretion of AMH occurs, causing male sex differentiation during fetal development. The AMH molecules bind to AMHRII (anti-Müllerian hormone receptor type II) regressing the Müllerian duct. The Leydig cells secrete testosterone to aid the male differentiation process by inducing structures such as the epididymis, vas deferens and seminal vesicles. However, with PMDS individuals, the Müllerian duct persists instead of regressing, either due to AMH secretion (PMDS Type I) or AMH receptors (PMDS Type II). PMDS is usually coincidentally found during surgery for inguinal hernia, or when searching for adult male infertility causes. Other diagnostic tests
Genetic
Another method for the confirmation of PMDS is genetic testing. It is not usually preferred because of its processing period and cost. With image screenings such as ultrasound and MRI, the condition can be efficiently confirmed. Genetic tests can identify those who hold the mutated gene, identify the family members chances and risks, and advise those who are trying to get pregnant. Genetic counseling and further genetic testing is offered to confirm the chances and risks of an individuals offspring obtaining the pair of mutated genes. Further research into the family tree and inheritance is possible as well. ELISA
An ELISA test is a form of immunoassay, a technique which uses an antibody or antigen to identify the presence of particular substances.